Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Oncological Biosimilars Shown to Be as Safe as Their Reference Products

August 13th 2023

By Gillian McGovern

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

Research Confirms Long-Term Stability of Adalimumab Biosimilar Candidate TUR01

August 12th 2023

By Deana Ferreri, PhD

A study on the stability of the adalimumab biosimilar candidate TUR01, a tumor necrosis factor-α inhibitor, found long-term stability of the drug substance and drug product were maintained under different temperatures.

The Top 5 Biosimilar Articles for the Week of August 7

August 11th 2023

By Justina Petrullo

Here are the top 5 biosimilar articles for the week of August 7, 2023.

Spanish Psoriasis Working Group Revises Guidelines for Biosimilars in Psoriasis

August 10th 2023

By Skylar Jeremias

The Spanish Psoriasis Working Group updated its position on the use of biosimilar medicines in patients with moderate to severe psoriasis, including its views on biosimilars as first-line treatment and nonmedical switching.

Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility

August 9th 2023

By Justina Petrullo

Streamlining biosimilar development would permit biosimilar development of more and a wider variety of biological drugs, fast-tracking biosimilar development without impacting patient safety or effectiveness, according to an opinion piece.

Challenges of Biosimilars With Interchangeable Designations

August 8th 2023

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Cost and Time Benefits of Interchangeable Biosimilars

August 8th 2023

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

Sintilimab Plus Bevacizumab Biosimilar vs Avastin Is Cost-Effective in HCC

August 8th 2023

By Skylar Jeremias

A Chinese study proved that combination therapy with sintilimab and a bevacizumab biosimilar was cost-effective enough in patients with hepatocellular carcinoma (HCC) to warrant use of the biosimilar over the reference product (Avastin) without compromising safety or efficacy.

BioRationality: The Adulthood of Biosimilars—Global Status and Future of Biosimilars

August 7th 2023

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, gives an overview of the global biosimilar landscape, noting why some countries have biosimilars, including follow-on biologics and unbranded biologics, for certain products and why others do not.

Biosimilars Immunology Roundup for July 2023—Podcast Edition

August 6th 2023

By Justina Petrullo

On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.